| NEUROCRINE BIOSCI. DL-001 |
| USA |
| Gesundheit |
| US64125C1099 / 900964 |
| NB3 (Frankfurt) / NBIX (NASDAQ) |
| FRA:NB3, ETR:NB3, NB3:GR, NASDAQ:NBIX |
| - |
| http://www.neurocrine.com.. |
|
Neurocrine Biosciences Inc. is a neuroscience-focused biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for neurological, neuropsychiatric, endocrine, and metabolic disorders. Its flagship produ..
>Volltext.. |
| 14884.65 Mio. EUR |
| 14097.95 Mio. EUR |
| 2725.23 Mio. EUR |
| 727.86 Mio. EUR |
| 587.32 Mio. EUR |
| 5.89 EUR |
| 356.82 Mio. EUR |
| 234.1 Mio. EUR |
| 758.7 Mio. EUR |
| 1.58 |
| 20.41% |
| 104.73% |
| - |
| - |
| - |
| 5 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 10.726.458 Euro. |
| NEUROCRINE |
| 30.06.26 |